Effects of levosimendan on diaphragm contractility in healthy subjects

Effects of levosimendan on diaphragm contractility in healthy subjects - Effects of levosimendan on the diaphragm

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35071

Enrollment

Registered

2009-11-30

Start date

2010-04-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory muscle weakness and fatigue weaning

Interventions

Subjects are treated with either levosimendan or placebo. Diaphragm strength and endurance is determined by measuring transdiaphragmatic pressure (Pdi) during magnetic stimulation of the phrenic ner

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age > 18 year - informed consent

Exclusion criteria

Exclusion criteria: - use of any prescript medication - chronic hiccups (defined as hiccups longer than 15 minutes in the past 6 months) - pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including diabetes and auto-immune diseases. - pre-existent lung disease - pre-existent cardiac disease- pregnancy, breast feeding - innability to obtain adequate view of the heart with transthoracic echocardiography - upper airway / esophageal pathology - recent (

Design outcomes

Primary

Measure	Time frame
The main study parameters are the transdiaphragmatic pressure, diaphragm efficiency, maximal inspiratory pressure and tenson time index before and after levosimendan infusion.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)